About the Hematologic Oncology Session
Hematologic oncology focuses on cancers that affect the blood, bone marrow, and lymphatic system. In recent years, research in this field has made significant strides in understanding the molecular mechanisms underlying hematologic malignancies like leukemia, lymphoma, and multiple myeloma. Advances in genomics have enabled the identification of specific genetic mutations driving these cancers, leading to the development of targeted therapies tailored to individual patients. Immunotherapy, particularly CAR-T cell therapy, has emerged as a promising approach for treating certain hematologic cancers by harnessing the power of the immune system to target and destroy cancer cells. Additionally, ongoing research aims to unravel the complexities of the tumor microenvironment and the role of the immune system in hematologic malignancies, paving the way for more effective treatment strategies and improved outcomes for patients.
Topics Covered in Hematologic Oncology
Acute Leukemias
B-Cell Lymphomas
Multiple Myeloma
CAR-T Therapy
Bispecific Antibodies
Stem Cell Transplant
Related Scientific Sessions at CIOC 2027
Why Attend the Hematologic Oncology Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Hematologic Oncology work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Hematologic Oncology research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Hematologic Oncology track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Hematologic Oncology Conference 2027 — FAQs
What is the Hematologic Oncology track at CIOC 2027?
The Hematologic Oncology track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Hematologic Oncology. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Hematologic Oncology sessions?
Cancer researchers and clinicians, educators and students with an interest in Hematologic Oncology are all welcome — whether presenting or attending.
Can I present my research in the Hematologic Oncology track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Hematologic Oncology sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Hematologic Oncology track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.
